Paysign Q1 2025 revenue up 41% to $18.6M, net income $2.59M; raises full-year guidance

Paysign, Inc.

2025-Q1 EPS reported $0.05 revenue$18,598,149

Total revenues $18.60M (+41% YoY); net income $2.59M ($0.05 diluted EPS) vs $309K ($0.01) in Q1 2024.
Adjusted EBITDA $4.96M (+193.3%); pharma patient affordability revenue surged 260.8% to 46.3% of revenue.
Added 14 net patient affordability programs (total 90); plasma revenue fell 9.2%, center count 484.
FY2025 guidance raised: revenue $72-74M, net income $6-7M ($0.10-$0.12 EPS), Adj. EBITDA $16-17M.
Q2 2025 revenue guided $18.5-19.0M; Gamma acquisition expected to generate $4-5M annual cash cost savings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.